Steven G. Terra

Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes

Christopher P. Cannon, Richard E. Pratley, Samuel Dagogo‐Jack et al. · New England Journal of Medicine · 2020 · 1.4K citations · Full text

Efficacy of Ertugliflozin on Heart Failure–Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease

Francesco Cosentino, Christopher P. Cannon, David Z.I. Cherney et al. · Circulation · 2020 · 237 citations · Full text

Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV)

Christopher P. Cannon, Darren K. McGuire, Richard E. Pratley et al. · American Heart Journal · 2018 · 202 citations · Full text

Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy ( <scp>VERTIS MET</scp> )

Julio Rosenstock, Juan P. Frías, Dénes Páll et al. · Diabetes Obesity and Metabolism · 2017 · 184 citations · Full text

??1-Adrenergic receptor polymorphisms and left ventricular remodeling changes in response to ??-blocker therapy

Steven G. Terra, Karen Hamilton, Daniel Pauly et al. · Pharmacogenetics and Genomics · 2005 · 171 citations